

Enabling personalized cancer care


oncobit

In collaboration with: University Hospital Zurich, University Medical Center Hamburg-Eppendorf and Massachusetts General Hospital.

Oncobit™ PM: Personalized Monitoring for Metastatic Uveal Melanoma

Previous studies have shown that radiological response fails to accurately predict survival outcome in uveal melanoma, as imaging often underestimates the benefit of Tebentafusp treatment (Hassel J, et al. N Engl J Med. 2023.). This limitation has led to the exploration of alternative biomarkers, with early reductions in circulating tumor DNA (ctDNA) emerging as a superior predictor of overall survival.

Using Oncobit™ PM, consisting of digital PCR assays and software, we demonstrated that the quantification of ctDNA dynamics is a powerful tool to monitor disease and treatment response.



Overall survival (OS) in patients with first line systemic therapy (Ipi/Nivo or Tebentafusp) stratified by ctDNA detection at baseline (A) or ctDNA detection at least once within 3 months after treatment start (B).

- ▶ **Early ctDNA clearance is a prognostic marker of therapy response** - non-detectable ctDNA at baseline and within 3 months strongly correlates with prolonged survival, supporting its role as a critical biomarker for disease and treatment monitoring.
- ▶ **Applicable beyond Tebentafusp** - Our findings indicate that ctDNA clearance serve as a prognostic marker not only for Tebentafusp-treated patients but also for those undergoing immunotherapy.
- ▶ **Oncobit™ PM enables standardized, ultrasensitive, and quantitative ctDNA measurements** - Our first-in-class IVDR-certified digital PCR test is rapid and inexpensive, enabling real-time decentralized treatment monitoring without requiring tumor material.

Let's Talk: info@oncobit.com

We have additional interesting data that further reinforce these findings. Let's set up a call to discuss how **Oncobit™ PM** can support your clinical and research needs.



2797

For professional use only. According to the In Vitro Diagnostic Regulation (EU 2017/746).

www.oncobit.com

